BioAge Labs, Inc (BIOA NASDAQ) stock market data APIs
$12.7627
0.16(1.3%)
as of December 12, 2025
Try our APIs with
free plan!
BioAge Labs, Inc Financial Data Overview
Price chart is built with
Anychart
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Prev. Close
12.7627
Open
12.841
High
13.0758
Low
12.6529
52 wk Range
2.88-13.1
Market Cap
462 M
P/E Ratio
0.9464
Shares Outstanding
35 855 K
Revenue
5 917 K
EPS
-0.56
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with BioAge Labs, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioAge Labs, Inc data using free add-ons & libraries
Get BioAge Labs, Inc Fundamental Data
BioAge Labs, Inc Fundamental data includes:
- Net Revenue: 5 917 K
- EBITDA: -89 528 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.5137
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioAge Labs, Inc News
New
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
Key Points BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. 10 stocks we l...
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innova...
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks declined Thursday afternoon with the NYSE Health Care Index dropping 0.5% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
